Oesophageal cancer: new developments in systemic therapy

Area of Science:

• Oncology
• Gastroenterology

Background:

• Oesophageal cancer, especially adenocarcinoma, is a virulent malignancy with a high rate of increase in Western countries.
• Metastatic disease is present at diagnosis in 50% of patients, and develops in most others.
• Current non-surgical management involves combined chemotherapy and radiotherapy, with preoperative chemoradiotherapy for locally advanced disease.

Purpose of the Study:

• To review the efficacy and toxicity of conventional treatments for oesophageal cancer.
• To explore the role of newer chemotherapeutic agents and targeted therapies.
• To discuss the development of new clinical trials combining novel agents with standard care.

Main Methods:

• Review of current treatment standards for oesophageal cancer.
• Evaluation of data from trials involving taxanes and irinotecan.
• Discussion of emerging targeted therapies and their combination with conventional treatments.

Main Results:

• Conventional 5-FU-cisplatin chemotherapy with radiation has limited efficacy and significant toxicity.
• Newer agents like taxanes and irinotecan show promising antitumour activity and better tolerance.
• Pathologic complete responses range from 20-40%, with 5-year survival at 25-35%.

Conclusions:

• There is a need for more effective treatments for oesophageal cancer due to the limitations of current therapies.
• Newer chemotherapeutic agents and targeted therapies represent a promising direction for improving patient outcomes.
• Future research will focus on combining these novel agents with conventional chemotherapy and radiation for oesophageal cancer management.